PURPOSE: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated. This study aimed to assess the effect of adjuvant chemotherapy initiation time on disease recurrence and survival in stage III colon cancer patients undergoing curative surgical resection. METHODS: The medical records of stage III colon cancer patients undergoing curative resection between February 2004 and December 2009 were reviewed. RESULTS: Of the 133 enrolled patients, 27 (20.3%) began adjuvant chemotherapy within 3 weeks of surgery, whereas 106 (79.7%) did after 3 weeks following surgery. Patients receiving chemotherapy within 3 weeks of surgery were less likely to experience recurrences than those beginning treatment later (11.1% vs. 33%, P = 0.018). The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014). However, no significant differences in overall survival were observed between the 2 groups. CONCLUSION: Adjuvant chemotherapy should be initiated as soon as a patient's clinical condition allows. Patients with stage III colon cancer may benefit from adjuvant chemotherapy initiated within 3 weeks of surgery.
PURPOSE: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancerpatients, published guidelines do not specify when it should be initiated. This study aimed to assess the effect of adjuvant chemotherapy initiation time on disease recurrence and survival in stage III colon cancerpatients undergoing curative surgical resection. METHODS: The medical records of stage III colon cancerpatients undergoing curative resection between February 2004 and December 2009 were reviewed. RESULTS: Of the 133 enrolled patients, 27 (20.3%) began adjuvant chemotherapy within 3 weeks of surgery, whereas 106 (79.7%) did after 3 weeks following surgery. Patients receiving chemotherapy within 3 weeks of surgery were less likely to experience recurrences than those beginning treatment later (11.1% vs. 33%, P = 0.018). The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014). However, no significant differences in overall survival were observed between the 2 groups. CONCLUSION: Adjuvant chemotherapy should be initiated as soon as a patient's clinical condition allows. Patients with stage III colon cancer may benefit from adjuvant chemotherapy initiated within 3 weeks of surgery.
Authors: Harilaos D Konstantinidis; Aristedis P Slavakis; Konstantinos D Ballas; Antonia C Sioga; Louise D Economou; Charalampos I Demertzidis; Theano T Pissanidou; Zoi S Athanasiadou; Athanasios K Sakadamis Journal: Dis Colon Rectum Date: 2007-01 Impact factor: 4.585
Authors: Bengt Glimelius; Olav Dahl; Björn Cedermark; Anders Jakobsen; Søren M Bentzen; Hans Starkhammar; Henrik Grönberg; Ragnar Hultborn; Maria Albertsson; Lars Påhlman; Kjell-Magne Tveit Journal: Acta Oncol Date: 2005 Impact factor: 4.089
Authors: I Chau; A R Norman; D Cunningham; D Tait; P J Ross; T Iveson; M Hill; T Hickish; F Lofts; D Jodrell; A Webb; J R Oates Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: Gyoung Tae Noh; Jeonghee Han; Min Soo Cho; Hyuk Hur; Kang Young Lee; Nam Kyu Kim; Byung Soh Min Journal: PLoS One Date: 2020-01-31 Impact factor: 3.240